Actively Recruiting

Phase 2
Age: 12Years - 40Years
All Genders
NCT07091279

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

Led by Jeremy Veenstra-vanderweele · Updated on 2026-03-30

60

Participants Needed

2

Research Sites

148 weeks

Total Duration

On this page

Sponsors

J

Jeremy Veenstra-vanderweele

Lead Sponsor

U

United States Department of Defense

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.

CONDITIONS

Official Title

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

Who Can Participate

Age: 12Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 12 and 40 years
  • Clinical diagnosis of Autism Spectrum Disorder
  • Severe challenging behaviors such as aggression, self-injury, or severe disruptive behavior occurring at least weekly over the past 2 months
  • Score in the ASD range on the Autism Diagnostic Observation Schedule at study entry or within the past 5 years
  • Clinical Global Impression Severity score of 4 or above at baseline
  • Aberrant Behavior Checklist-2 Irritability/Agitation Subscale score of 18 or above at screening
  • Resting pulse greater than 60 and resting blood pressure greater than 100/60
  • Has a designated study partner spending at least 5 hours per week with the participant to provide reliable behavior reports and safety monitoring
  • Participants of childbearing potential who are sexually active agree to use effective contraception from screening through 30 days after last study drug dose
  • Participant can fully swallow study medication capsules
  • English is the primary language for the participant, and the study partner can consent and complete study forms in English
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent and no parent/guardian/legal representative available to consent
  • Change in psychotropic medication or behavioral intervention within 2 months before randomization (except for vocational, habilitation, or school schedule changes)
  • Asthma or history of bronchoconstriction disorders in the past 5 years
  • Cardiovascular conditions contraindicating high-dose propranolol use as determined by a cardiologist
  • Uncontrolled seizure disorder (seizure within past year or medication changes in past 6 months)
  • Diabetes mellitus
  • History of lactose intolerance requiring avoidance of dairy or lactase supplements
  • Renal or hepatic impairment
  • History of hypoglycemia
  • Unable to provide blood testing when medically indicated for safety
  • Current or recent depressive episode within past 6 months
  • Allergy or adverse reaction to propranolol or other beta-blockers
  • Current use of certain medications including propafenone, quinidine, amiodarone, lidocaine, digitalis glycosides, calcium channel blockers, ACE inhibitors, clonidine, alpha blockers, reserpine, epinephrine, isoproterenol, dobutamine, indomethacin, MAO inhibitors, tricyclic antidepressants, methoxyflurane, trichloroethylene, warfarin, haloperidol, thyroxine, or alcohol
  • Any other medical condition or medication contraindicating propranolol
  • Judged inappropriate for the study by the investigator
  • Participation in another investigational medication or device study within the last 3 months
  • Unable to complete blood pressure or ECG safety assessments
  • Pregnant or breastfeeding if female

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

New York State Institute for Basic Research (IBR)

Staten Island, New York, United States, 10314

Actively Recruiting

2

Center for Autism and the Developing Brain

White Plains, New York, United States, 10605

Actively Recruiting

Loading map...

Research Team

S

Suvekcha Bhattachan, MA

CONTACT

A

Alyssa Verdes, BA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism | DecenTrialz